Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas | Zendy

Stephen J. Schuster | Zendy; Jakub Svoboda | Zendy; Elise A. Chong | Zendy; Sunita D. Nasta | Zendy; Anthony R. Mato | Zendy; Özlem Anak | Zendy; Jennifer L. Brogdon | Zendy; Iulian Pruteanu-Malinici | Zendy; Vijay Bhoj | Zendy; Daniel J. Landsburg | Zendy; Mariusz A. Wasik | Zendy; Bruce L. Levine | Zendy; Simon F. Lacey | Zendy; J. Joseph Melenhorst | Zendy; David L. Porter | Zendy; Carl H. June | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Author(s) -

Stephen J. Schuster,

Jakub Svoboda,

Elise A. Chong,

Sunita D. Nasta,

Anthony R. Mato,

Özlem Anak,

Jennifer L. Brogdon,

Iulian Pruteanu-Malinici,

Vijay Bhoj,

Daniel J. Landsburg,

Mariusz A. Wasik,

Bruce L. Levine,

Simon F. Lacey,

J. Joseph Melenhorst,

David L. Porter,

Carl H. June

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1708566

Subject(s) - follicular lymphoma , medicine , lymphoma , chimeric antigen receptor , diffuse large b cell lymphoma , immunology , cytokine release syndrome , transplantation , oncology , immune system , immunotherapy

Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research